Chestnut Hill, MA, United States of America

Michael Chorev

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Biotechnology Research. Top assignees: Harvard College, Abiogen Pharma S.p.a., Beth Israel. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Chorev. Retrieved from https://idiyas.com/inventor/michael-chorev-4455dok8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 80.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 29(Granted Patents)

Company Filing History:

Abiogen Pharma S.p.a.

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

patents

6. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

Glycated CD59 Peptides

Anti-CD59 Antibodies

Gestational Diabetes

Post-Translational Modifications

Quality Control Bioassays

N,N'-Diarylurea Compounds

Cellular Proliferation Inhibition

Protein Synthesis Regulation

Bone Anabolic Agents

PTH2 Receptor Compounds

PTH-Like Peptides

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891448 - Glycated CD59 peptides, their preparation, and uses thereof (2024-02-06),

2. 11866506 - Anti-CD59 antibodies (2024-01-09),

3. 11161910 - Glycated CD59 peptides, their preparation, and uses thereof (2021-11-02),

4. 10732186 - Methods and reagents for the assessment of gestational diabetes (2020-08-04),

5. 10309973 - Surrogates of post-translationally modified proteins and uses thereof (2019-06-04),

6. 9952200 - Cell based quality control bioassays for nutriceutical and medicinal products (2018-04-24),

7. 9932300 - N,N'-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation (2018-04-03),

8. 9421211 - N,N'-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation (2016-08-23),

9. 9417248 - Surrogates of post-translationally modified proteins and uses thereof (2016-08-16),

10. 9068006 - Glycated CD59 peptides, their preparation, and uses thereof (2015-06-30),

11. 8969573 - Compounds for the inhibition of cellular proliferation (2015-03-03),

12. 8257931 - Regulation of protein synthesis (2012-09-04),

13. 7799757 - Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents (2010-09-21),

14. 7531621 - PTH2 receptor selective compounds (2009-05-12),

15. 7132394 - PTH-like peptides (2006-11-07),

Title: Michael Chorev: Innovator in Diabetes Research

Introduction

Michael Chorev is a prominent inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of diabetes research, holding a total of 15 patents. His work focuses on innovative methods for diagnosing and treating diabetes, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents is the invention titled "Glycated CD59 peptides, their preparation, and uses thereof." This invention provides glycated Amadori products of the CD59 peptide and its fragments, which can be utilized as tools for the diagnosis and prognosis of pre-diabetes and diabetes. The invention includes methodologies for generating antibodies and antibody fragments related to these glycated products. Another notable patent is for "Anti-CD59 antibodies," which discloses various assays, diagnostics, kits, and components that incorporate these antibodies. These inventions also encompass methods for assessing diabetes-related indications and evaluating inhibitors of CD59 glycation.

Career Highlights

Michael Chorev has worked with prestigious institutions, including Harvard College. His research has led to groundbreaking advancements in understanding diabetes and developing diagnostic tools that can significantly impact patient care.

Collaborations

Throughout his career, Chorev has collaborated with notable professionals in the field, including Jose Alberto Halperin and Bertal Huseyin Aktas. These collaborations have further enriched his research and contributed to the success of his inventions.

Conclusion

Michael Chorev's innovative work in diabetes research exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to pave the way for advancements in diabetes diagnosis and treatment.

Profile summary based on public USPTO records.